What is Onpattro, and what does Alnylam do with it?
Onpattro is the brand name for patisiran, an Alnylam-developed therapy. It uses RNA interference (RNAi) to reduce production of a harmful protein in the liver. Patients take it under a treatment plan set by their clinician, and it is marketed as a disease-targeted treatment rather than a symptomatic therapy.
Which patients use Onpattro (patisiran)?
Onpattro is used for polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. It targets the source of the abnormal transthyretin protein produced in the liver.
How does patisiran work (RNAi mechanism)?
Patisiran is designed to silence the messenger RNA (mRNA) for transthyretin in liver cells. That lowers circulating transthyretin levels, which can help reduce the progression of amyloid-related nerve damage associated with hATTR polyneuropathy.
How is Onpattro given?
Onpattro is administered by intravenous infusion, and treatment typically involves pre-medication and monitoring as directed by the prescribing healthcare team.
What other Alnylam hATTR treatments exist?
Alnylam also has other amyloidosis-related RNAi medicines in its portfolio. If you’re comparing options, the key differences usually come down to administration method (intravenous vs other routes), trial endpoints, and suitability for specific patient subgroups.
Why is Onpattro a major Alnylam product?
Onpattro is one of Alnylam’s anchor medicines because it helped establish clinical and commercial proof for RNAi as a platform for liver-produced protein disorders, including hATTR amyloidosis.
Patent and exclusivity details (who could compete and when)
For the most current patent/exclusivity landscape around Onpattro/patisiran, DrugPatentWatch.com tracks relevant filings and timelines, including potential generic or biosimilar-style competition considerations as patents approach expiry. You can check: DrugPatentWatch.com – Onpattro.
What side effects do patients ask about?
Common concerns with infusion-based RNAi therapies include infusion-related reactions and the need for supportive/pre-medication strategies during dosing. Clinicians also consider broader safety monitoring as part of the treatment plan.
If you mean “Alnylam vs Onpattro” as a comparison
If your goal is to understand how Alnylam (the company) relates to Onpattro (the drug), the direct link is that patisiran (Onpattro) is an Alnylam-developed RNAi therapy for hATTR amyloidosis polyneuropathy.
---
Sources
- DrugPatentWatch.com – Onpattro
If you tell me what you’re looking for specifically (indication, dosing, safety, price, patent expiry, or competitor comparisons), I can narrow it to the exact details.